论文部分内容阅读
药品是中国重要的卫生资源。尽管上市前药品研究已受到相当重视,但对上市后药品的实际问题关注较少。合理使用和分配上市后药品资源是中国的决策者面临的主要问题之一。经济学评价作为优化分配和使用药品的有效工具现已得到公认。本文介绍了上市后药物的经济学评价方法与原则。上市后药物的经济学评价根据证据的有效性和数量分为三种情况,并相应地采取不同的研究方法。但上市后药物经济学评价方法应采取标准路径。此外,本文还介绍了建立经济学评价框架和评价经济学证据的方法,特别是针对同类药物的评价方法。
Drugs are an important health resource in China. Although pre-market drug research has received considerable attention, less attention is paid to the practical problems of post-marketing pharmaceuticals. The rational use and distribution of post-market pharmaceutical resources is one of the major problems facing Chinese policymakers. Economic valuation is now recognized as an effective tool for optimizing the distribution and use of medicines. This article describes the methods and principles of economic evaluation of post-marketing drugs. After the listing of the economic evaluation of drugs according to the validity and quantity of evidence is divided into three cases, and accordingly adopt different research methods. However, after the listing of pharmacoeconomic evaluation methods should take a standard path. In addition, this article also describes the establishment of economic evaluation framework and evaluation of economic evidence, especially for the evaluation of similar drugs.